The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Mosunetuzumab induces CR in B-NHL R/R to CAR-T
Stephen Schuster, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses an open-label, multicenter, Phase I/Ib, dose escalation and expansion study of mosunetuzumab in patients with B-cell non-Hodgkin lymphoma (NHL), who are relapsed/refractory to CAR-T therapies or for those a delay in effective therapy prevents this approach (GO29781; NCT02500407). Preliminary data support that mosunetuzumab has favorable tolerability and durable efficacy in heavily pre-treated relapsed or refractory B-cell NHL. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
